Limited partnership

Holiday Island Holdings, Inc. is Developing Multiple Income Producing Oil Wells in West Texas

Retrieved on: 
Dienstag, Januar 30, 2024
HOLIDAY, Permian, Limited partnership, News, Klinker, Oil, Investment, OTC, Partnership

HOLIDAY ISLAND, Ark., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Holiday Island Holdings, Inc. (OTC: HIHI) (Pending name change to EP3Oil) – operating in the Secondary Recovery of Oil & Gas Industry – released the news today that Holiday Island Holdings finalized a deal for multiple Oil Wells in West Texas Permian Basin.

Key Points: 
  • HOLIDAY ISLAND, Ark., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Holiday Island Holdings, Inc. (OTC: HIHI) (Pending name change to EP3Oil) – operating in the Secondary Recovery of Oil & Gas Industry – released the news today that Holiday Island Holdings finalized a deal for multiple Oil Wells in West Texas Permian Basin.
  • Glenn Klinker (CEO Holiday Island Holdings) has finalized a deal to develop multiple wells with Benchmark Petroleum and Rock Oil in the Permian basin of Texas.
  • Alverico Asencio, VP of Holiday Island Holdings, has strong partnerships in South America and the United States, and he is confident in his ability to fund these endeavors.
  • Asencio is quoted, “I have been inundated with multiple inquiries into the purchase of Oil Opportunities, especially from the Dominican Republic and Ecuador.

EQS-News: paragon founder bundles shares in family holding

Retrieved on: 
Dienstag, Januar 30, 2024
Limited partnership, Paragon, Federal Financial Supervisory Authority, Federal, Gesellschaft mit beschränkter Haftung

Klaus Dieter Frers has transferred his 49.3% share package in paragon GmbH & Co. KGaA to Frers Family Office GmbH

Key Points: 
  • Klaus Dieter Frers has transferred his 49.3% share package in paragon GmbH & Co. KGaA to Frers Family Office GmbH
    Frers Family Office GmbH is now the largest shareholder of paragon GmbH & Co. KGaA
    Delbrück, January 26, 2024 - The founder of paragon GmbH & Co. KGaA [ISIN DE0005558696], Klaus Dieter Frers, has informed the company that both he and his wife have transferred all paragon shares they own to Frers Family Office GmbH.
  • According to Klaus Dieter Frers, Managing Director of the general partner of paragon GmbH & Co. KGaA, paragon GmbH, the bundling had been planned for some time, but could only be implemented after the repurchase of a block of shares last year.
  • Mr. Klaus Dieter Frers holds approximately 98.6% of the shares in Frers Family Office GmbH, which is based in Delbrück.
  • Klaus Dieter Frers is also Managing Director of the company, which functions as a family holding company.

Percent Wraps 2023 with Significant Growth and Crosses $1 Billion Threshold in Marketplace Issuance

Retrieved on: 
Mittwoch, Januar 24, 2024
Banking, Fintech, Professional Services, Finance, Limited partnership, Investment, AUM, Growth, Cryptocurrency

Percent , the platform that has created the modern private credit marketplace, closed out 2023 with a record-setting performance.

Key Points: 
  • Percent , the platform that has created the modern private credit marketplace, closed out 2023 with a record-setting performance.
  • Notably, the platform crossed the $1 billion threshold in marketplace issuance across more than 550 deals (as of January 9, 2024) since the company’s founding in 2018.
  • In 2023, Percent raised $30M in a Series B round that helped fuel the company’s growth and mission.
  • Total AUM saw a 35.7% increase YOY from 2022 to 2023, and has increased an average of 41.4% yearly since 2021.

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

Retrieved on: 
Mittwoch, Januar 10, 2024
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, Constellation, Patient, Therapy, Biology, Remyelination, Drug design, ALS, Broad Institute, Multiple sclerosis, Partnership, Harvard Medical School, National academy, GPR17, Venture, Neuroinflammation, MIT, Sympathetic nervous system, Drug development, TYK2, Traffic barrier, Harvard University, Capital, Limited partnership, CNS, Pharmaceutical industry

Myrobalan has the potential to overcome such obstacles with the development of highly selective, brain-penetrant, orally available compounds against promising novel targets involved in demyelination and neuroinflammation.

Key Points: 
  • Myrobalan has the potential to overcome such obstacles with the development of highly selective, brain-penetrant, orally available compounds against promising novel targets involved in demyelination and neuroinflammation.
  • These currently untreatable disease mechanisms have been linked to multiple sclerosis (MS), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and several rare neurological conditions.
  • “Our deep understanding of remyelination and neuroinflammation has broad application in high-unmet need CNS diseases,” said Dr. Jing Wang, CEO & Co-Founder, Myrobalan Therapeutics.
  • Myrobalan Therapeutics' unique strategy holds great promise in overcoming challenges associated with central nervous system diseases.

Cheetah Mobile Further Invests in Beijing OrionStar

Retrieved on: 
Freitag, Januar 12, 2024
Artificial intelligence, Research, AGI, Limited partnership, LLM, Automotive industry

BEIJING, Jan. 12, 2024 /PRNewswire/ -- Cheetah Mobile Inc. (NYSE: CMCM) ("Cheetah Mobile" or the "Company"), a leading internet company, today announced that the Company, through two of its wholly-owned subsidiaries, has made an additional investment in Beijing OrionStar Technology Co., Ltd. ("Beijing OrionStar"), in which the Company held 72.91% equity interest before the investment.

Key Points: 
  • BEIJING, Jan. 12, 2024 /PRNewswire/ -- Cheetah Mobile Inc. (NYSE: CMCM) ("Cheetah Mobile" or the "Company"), a leading internet company, today announced that the Company, through two of its wholly-owned subsidiaries, has made an additional investment in Beijing OrionStar Technology Co., Ltd. ("Beijing OrionStar"), in which the Company held 72.91% equity interest before the investment.
  • The Company, through a wholly-owned subsidiary, made an investment of US$16.7 million in Beijing OrionStar.
  • Concurrently, Beijing Kingsoft Internet Security Software Co., Ltd. ("Beijing Security"), a wholly-owned subsidiary of the Company, exercised its right under the convertible loan with principal amount of RMB100 million that it provided to Beijing OrionStar in 2021 to convert all of the principal and the accrued interest into Beijing OrionStar's equity interest.
  • Additionally, Gongqingcheng Orion Industrial Investment Center (Limited Partnership) (the "Fund") made an investment of RMB150 million, or approximately US$20.9 million, into Beijing OrionStar.

Evolve Transition Infrastructure Reports Exercise of Right to Purchase Common Units

Retrieved on: 
Montag, Januar 8, 2024
Limited partnership, General partnership, SNMP, Security (finance)

HOUSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evolve Transition Infrastructure LP (NYSE American: SNMP) (the “Partnership”) announced today that Evolve Transition Infrastructure GP LLC, the general partner of the Partnership (the “General Partner”), has elected to exercise the right to purchase all of the issued and outstanding common units representing limited partner interests (“Common Units”) in the Partnership not already owned by the General Partner or its controlled affiliates (the “Transaction Units”) pursuant to Section 15.1 of the Partnership’s Third Amended and Restated Agreement of Limited Partnership, as amended (the “Partnership Agreement”).

Key Points: 
  • HOUSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evolve Transition Infrastructure LP (NYSE American: SNMP) (the “Partnership”) announced today that Evolve Transition Infrastructure GP LLC, the general partner of the Partnership (the “General Partner”), has elected to exercise the right to purchase all of the issued and outstanding common units representing limited partner interests (“Common Units”) in the Partnership not already owned by the General Partner or its controlled affiliates (the “Transaction Units”) pursuant to Section 15.1 of the Partnership’s Third Amended and Restated Agreement of Limited Partnership, as amended (the “Partnership Agreement”).
  • The General Partner will purchase the Transaction Units on February 16, 2024 (the “Purchase Date”) for a cash purchase price of $1.389285 per Transaction Unit.
  • As of the Purchase Date, all rights of the holders of the Transaction Units will cease, except for the right to receive payment of the purchase price.
  • Upon completion of the purchase on the Purchase Date, the General Partner and its affiliates will own, directly or indirectly, 100% of the Common Units.

EQS-News: CGM continues to drive digitization in healthcare and reports 10 % revenue growth in first nine months

Retrieved on: 
Samstag, Dezember 30, 2023
Health, CGM, Physician, Hospital, AI, Traction, Limited partnership, Pharmacy, Growth, EUR, Patient, Intelligence, Medical device

CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, successfully progressed the digitization in healthcare during the first three quarters in 2023.

Key Points: 
  • CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, successfully progressed the digitization in healthcare during the first three quarters in 2023.
  • Together with the gematik, CGM has supported its customers – doctors, hospitals and pharmacies – in the third quarter to drive the usage of e-Prescriptions for the benefit of patients.
  • The German governmental initiative for the modernization and digitization of hospitals is a key growth driver in CGM's hospital information systems segment.
  • Also, CGM is increasingly providing clinical rehab customers with connectivity solutions, thereby laying the foundation for further digitization measures.

Axelspace Raises $44 Million, Closing Series D Funding Round to Accelerate Growth Toward Social Implementation of Microsatellite Applications

Retrieved on: 
Donnerstag, Dezember 21, 2023
Other Manufacturing, Technology, Research, Satellite, Aerospace, Manufacturing, Hardware, Data Management, Science, BANK, JAXA, Sumitomo Mitsui Banking Corporation, Limited partnership, Area studies, Security (finance)

Axelspace Holdings Corporation today announced that the company completed its Series D funding round raising approximately JPY 6.24 billion (equivalent to USD 44.0 million).

Key Points: 
  • Axelspace Holdings Corporation today announced that the company completed its Series D funding round raising approximately JPY 6.24 billion (equivalent to USD 44.0 million).
  • The round sees the allocation of new shares to SMBC-GB Growth I Investment Limited Partnership, several other venture capitals, and corporate investors.
  • Axelspace Corporation, a wholly owned subsidiary of Axelspace Holdings, will use the new funds to meet more diverse customer demands.
  • We will continue to work toward the realization of our vision, "Space within Your Reach," by accelerating societal applications of microsatellites.

Proxygen Announces Formation of Scientific Advisory Board

Retrieved on: 
Mittwoch, November 15, 2023
MSD, DRS, Broad Institute, DNA, Limited partnership, National academy, Dana–Farber Cancer Institute, Patient, Research, Ubiquitin, Pharmacology, Therapy, Chromatin, Pioneer, Drug discovery, Cancer, Diabetes, Harvard University, Field, Howard Hughes Medical Institute, Translation, Organization, MIT, European, Jude the Apostle, Merck & Co., Austrian Academy of Sciences, Max Planck Society, Translational medicine, Leibniz Prize, JDRF, Pancreatic cancer, Ernst Jung Prize, Biochemistry, SAB, EMBO, Publishing, Louis-Jeantet Prize for Medicine, Pharmacia, Glioblastoma, Boehringer Ingelheim, Medicine, Biotechnology, Genomics, Doctor of Philosophy, Monroe Dunaway Anderson, Biology, DNA repair, Pharmaceutical industry, Science, Merck

VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB). The newly appointed SAB, which is comprised of highly regarded thought leaders in the emerging field of protein degradation, will offer scientific expertise and guidance to Proxygen as the company works to advance its internal molecular glue degrader programs toward clinical development. In addition to its internal programs, Proxygen is also actively engaged in strategic research collaboration and license agreements with Merck & Co (known as MSD outside the U.S. and Canada), Boehringer Ingelheim and Merck KGaA designed to jointly identify and develop novel molecular glue degraders.

Key Points: 
  • SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine
    VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB).
  • Schulman and Draetta to the Proxygen team as key advisors and pair them with Drs.
  • Winter and Kubicek, who co-founded the company, based on their trailblazing research at CeMM,” said Bernd Boidol, Ph.D., chief executive officer of Proxygen.
  • By streamlining and fully integrating cutting-edge genomic, proteomic, and biochemical technologies, Proxygen has successfully developed a highly versatile glue degrader discovery engine.

MultiMetaVerse Announces Updates of the Taomee Acqusition and Termination of Prior Acquisition Agreement

Retrieved on: 
Mittwoch, November 29, 2023
Acquisition, MMV, Animation, Limited partnership, Target, Agreement, Letter, Good, Commercial property, Bank, Orient

On September 15, 2023, MMV announced that it had entered into an acquisition agreement (the "Agreement") to acquire 100% equity in Shanghai Shengran Information Technology Co., Ltd. and associated interests pertaining to all of its consolidated variable interest entities (collectively, the "Target Group," or "Taomee").

Key Points: 
  • On September 15, 2023, MMV announced that it had entered into an acquisition agreement (the "Agreement") to acquire 100% equity in Shanghai Shengran Information Technology Co., Ltd. and associated interests pertaining to all of its consolidated variable interest entities (collectively, the "Target Group," or "Taomee").
  • The closing of the Agreement was conditioned upon, among others, MMV's payment of the transaction consideration in installments within a fixed period of time.
  • MMV believes that the Target Group is a valuable asset with synergy to the Company, and intends to further pursue the transaction contemplated under the Agreement.
  • In particular, MMV has entered into a share subscription agreement with Eagle Creek LP with a total proceed of US$15,000,000.